BG64338B1 - Производни на доластатин-15 в комбинация с таксани - Google Patents

Производни на доластатин-15 в комбинация с таксани Download PDF

Info

Publication number
BG64338B1
BG64338B1 BG103728A BG10372899A BG64338B1 BG 64338 B1 BG64338 B1 BG 64338B1 BG 103728 A BG103728 A BG 103728A BG 10372899 A BG10372899 A BG 10372899A BG 64338 B1 BG64338 B1 BG 64338B1
Authority
BG
Bulgaria
Prior art keywords
compound
formula
pro
tert
carbonyl
Prior art date
Application number
BG103728A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103728A (en
Inventor
Teresa Barlozzari
Andreas Haupt
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG103728A publication Critical patent/BG103728A/xx
Publication of BG64338B1 publication Critical patent/BG64338B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG103728A 1997-03-13 1999-09-13 Производни на доластатин-15 в комбинация с таксани BG64338B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/819,101 US6103698A (en) 1997-03-13 1997-03-13 Dolastatin-15 derivatives in combination with taxanes

Publications (2)

Publication Number Publication Date
BG103728A BG103728A (en) 2000-04-28
BG64338B1 true BG64338B1 (bg) 2004-10-29

Family

ID=25227196

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103728A BG64338B1 (bg) 1997-03-13 1999-09-13 Производни на доластатин-15 в комбинация с таксани

Country Status (30)

Country Link
US (2) US6103698A (ko)
EP (1) EP0981358B1 (ko)
JP (1) JP2001514659A (ko)
KR (1) KR100555604B1 (ko)
CN (1) CN1157223C (ko)
AT (1) ATE241376T1 (ko)
AU (1) AU728027B2 (ko)
BG (1) BG64338B1 (ko)
BR (1) BR9808249A (ko)
CA (1) CA2282720C (ko)
CO (1) CO4940498A1 (ko)
CZ (1) CZ293905B6 (ko)
DE (1) DE69815100T2 (ko)
DK (1) DK0981358T3 (ko)
ES (1) ES2200317T3 (ko)
HK (1) HK1026851A1 (ko)
HR (1) HRP980125A2 (ko)
HU (1) HU228860B1 (ko)
ID (1) ID23900A (ko)
IL (2) IL131597A0 (ko)
NO (1) NO323894B1 (ko)
NZ (1) NZ337416A (ko)
PL (1) PL197834B1 (ko)
PT (1) PT981358E (ko)
RU (1) RU2218174C2 (ko)
SK (1) SK285133B6 (ko)
TR (1) TR199902244T2 (ko)
TW (1) TWI277426B (ko)
WO (1) WO1998040092A1 (ko)
ZA (1) ZA982093B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US20050192443A1 (en) * 2000-11-08 2005-09-01 Lorus Therapeutics Inc. Biological response modifier for the treatment of cancer
WO2002038164A1 (en) * 2000-11-08 2002-05-16 Lorus Therapeutics Inc. Combination preparation of a biological response modifier and an anticancer agent and uses thereof
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
TW202210498A (zh) * 2020-06-03 2022-03-16 日商中外製藥股份有限公司 高難度序列之有效率的胜肽縮合法
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
CA2115355C (en) 1991-08-09 2007-09-11 Kyoichi Sakakibara Novel tetrapeptide derivative
US5227400A (en) * 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) * 1992-03-13 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CA2151953A1 (en) * 1992-12-16 1994-06-23 Andreas Haupt "dolostatin analog" (novel peptides, the preparation and use thereof)
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (en) 1993-09-29 1995-03-30 George Weber Method for the treatment of neoplastic disease utilizing taxol and tiazofurin
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) * 1994-06-02 1996-02-27 Shimizu; Yuzuru Caribenolide I
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
WO1996018401A1 (en) 1994-12-15 1996-06-20 Baker Norton Pharmaceuticals, Inc. Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound

Also Published As

Publication number Publication date
ZA982093B (en) 1999-09-12
ES2200317T3 (es) 2004-03-01
RU2218174C2 (ru) 2003-12-10
IL131597A0 (en) 2001-01-28
HU228860B1 (en) 2013-06-28
ATE241376T1 (de) 2003-06-15
KR100555604B1 (ko) 2006-03-03
AU6694598A (en) 1998-09-29
AU728027B2 (en) 2001-01-04
HK1026851A1 (en) 2000-12-29
SK285133B6 (sk) 2006-07-07
IL131597A (en) 2006-06-11
HUP0001381A2 (hu) 2000-10-28
TWI277426B (en) 2007-04-01
PL335579A1 (en) 2000-05-08
ID23900A (id) 2000-05-25
CZ321199A3 (cs) 2000-02-16
TR199902244T2 (xx) 1999-12-21
SK125199A3 (en) 2000-08-14
CA2282720A1 (en) 1998-09-17
NZ337416A (en) 2001-05-25
BR9808249A (pt) 2000-05-16
HRP980125A2 (en) 1999-02-28
WO1998040092A1 (en) 1998-09-17
NO994408D0 (no) 1999-09-10
EP0981358B1 (en) 2003-05-28
CA2282720C (en) 2009-12-29
CN1252728A (zh) 2000-05-10
DE69815100D1 (de) 2003-07-03
KR20000076211A (ko) 2000-12-26
NO994408L (no) 1999-11-10
JP2001514659A (ja) 2001-09-11
NO323894B1 (no) 2007-07-16
PL197834B1 (pl) 2008-04-30
CZ293905B6 (cs) 2004-08-18
BG103728A (en) 2000-04-28
CO4940498A1 (es) 2000-07-24
US6103698A (en) 2000-08-15
PT981358E (pt) 2003-09-30
DK0981358T3 (da) 2003-09-22
HUP0001381A3 (en) 2001-12-28
EP0981358A1 (en) 2000-03-01
DE69815100T2 (de) 2004-02-05
US6632795B1 (en) 2003-10-14
CN1157223C (zh) 2004-07-14

Similar Documents

Publication Publication Date Title
AU679479B2 (en) Dolostatin analog
PL185763B1 (pl) Nowe peptydy stanowiące pochodne dolastatyny, ichzastosowanie w medycynie oraz kompozycja farmaceutyczna
AU669710B2 (en) Derivatives of dolastatin
EP0981358B1 (en) Dolastatin-15 derivatives in combination with taxanes
AU748465B2 (en) Methods and compositions for treating rheumatoid arthritis
IL166853A (en) Antineoplastic peptides, their preparation and various uses thereof
US8440626B2 (en) Antineoplastic peptides
MXPA99008066A (en) Dolastatin-15 derivatives in combination with taxanes
CZ20001211A3 (cs) Prostředky pro léčení revmatoidní artritidy
PL178351B1 (pl) Nowe peptydy